MindMed Q3 net loss $13.7M; cash $295.3M; Phase 3 Voyage on track for Q4 2024

Definium Therapeutics, Inc.

2024-Q3 EPS reported -$1.12

Net loss $13.7M vs $17.9M a year ago; R&D expenses $17.2M (up $4.0M YoY) on MM120/MM402 programs.
Cash and equivalents $295.3M as of Sep 30, 2024; expected to fund operations into 2027.
Phase 3 Voyage study of MM120 ODT in GAD to start Q4 2024; 12-week topline data expected H1 2026.
Phase 3 Panorama (GAD) and Phase 3 Emerge (MDD) studies on track to initiate in H1 2025.
Completed Phase 1 study of MM402 (R(-)-MDMA) for Autism Spectrum Disorder in October 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.